UPDATE : Tuesday, June 19, 2018
상단여백
HOME Special
CJ Healthcare goes up for sale, gathers worldwide attention from domestic pharma to foreign investorsTop 10 pharmaceutical stories in 2017 ④
  • By Korea Biomedical Review
  • Published 2017.12.27 12:20
  • Updated 2017.12.27 12:57
  • comments 0

The Korean pharmaceutical industry continued to grow this year, with the market size exceeding a historical 20 trillion won ($18.5 billion) landmark. Global success stories of Celltrion and Samsung Bioepis are ongoing news, and more Korean pharmaceuticals are entering the U.S. market. Kolon Life Science released the new, domestically-developed drug Invossa and other Korean pharmaceutical firms followed suit. Illegal rebates remained a current problem while patients expressed outrage against high drug prices. The government unveiled policies that slashed drug costs to regulate prices, keeping pharmaceuticals on their feet. The following are the 10 biggest pharmaceutical stories in 2017 – Ed.

The CJ Group turned heads when it announced its decision to sell CJ Healthcare, the healthcare division of the conglomerate that once neared public listing.

The group announced it would sell the division that CJ CheilJedang acquired through Yoopoong Pharmaceutical 33 years ago. CJ Group tapped Morgan Stanley to conduct the sale to potential bidders.

Industry insiders say the sell-off comes as a restructuring effort by CJ Group to concentrate efforts on the conglomerate’s competitive areas of logistics and art and culture.

Around seven domestic and foreign organizations participated in the preliminary tender for CJ Healthcare this month. Potential buyers included Kolmar Korea, MBK Partners, Bain Capital, Carlyle, TPG and CVC Capital. Of them, Kolmar Korea and SI Investments expressed intentions to buy, making them the strongest candidates. Bain Capital, which acquired Hugel, is also looking toward securing a pipeline by purchasing CJ Healthcare.

The CJ Group, which has a 100 percent stake in the healthcare division, is reportedly demanding 1.5 trillion won ($1.39 billion) for the unit.

webmaster@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Korea Biomedical Review
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top